

# COVID-19 Vaccine Development and the Complex Job of Meeting Global Demand

**Thomas B. Cueni**

Director General

International Federation of Pharmaceutical Manufacturers & Associations

# Nobody is safe from the virus until we all are



## Covid-19 vaccine: First person receives Pfizer jab in UK

At University Hospital, Coventry, matron May Parsons administered the very first injection to Ms Keenan.

"I feel so privileged to be the first person vaccinated against Covid-19," said Ms Keenan, who is originally from Enniskillen, Co Fermanagh.

"It's the best early birthday present I could wish for because it means I can finally look forward to spending time with my family and friends in the new year, after being on my own for most of the year.

"My advice to anyone offered the vaccine is to take it. If I can have it at 90, then you can have it too," she added.




We share joint concerns of COVID-19 vaccine acceptance and understanding of the need for public's questions about vaccine safety.

# COVID-19 Global Biopharmaceutical Industry Commitment to Address Coronavirus Public Health Crisis




Repurpose existing and test new treatments



Share real-time clinical trial data with governments and other companies



Speed up R&D of safe and effective vaccines



Develop diagnostic testing and secure continuous supply



Secure essential supplies for medicines and vaccines



Increase and share manufacturing capacity for medicines and vaccines



Support global healthcare systems

# IFPMA has joined the global public-private partnership, ACT Accelerator, as founding partner

## ***Pandemic called for a new type of end-to-end public-private partnership***

We stand ready to bring to this partnership our unique knowledge and expertise in the discovery and development of medicines and vaccines, as well as our experience building manufacturing capacity and distribution networks.

We are proud to be part of this landmark global partnership and are fully committed to its goal to accelerate development, production and equitable global access to safe, quality, effective, and affordable COVID-19 therapeutics and vaccines. In the fight against COVID-19, we must ensure that no one is left behind”.

***“We will only succeed in this journey together”.***

Statements delivered by Dave Ricks, CEO Eli Lilly and Company and President IFPMA and Thomas Cueni, DG IFPMA

# ACTaccelerator

## ACCESS TO COVID-19 TOOLS

### ACCESS TO COVID-19 TOOLS (ACT) ACCELERATOR

A Global Collaboration to Accelerate the Development, Production and Equitable Access to New COVID-19 diagnostics, therapeutics and vaccines

### COMMITMENT and CALL TO ACTION



**Vaccine**  
2 Billion doses  
by the end  
of 2021



**Therapeutics**  
245 million courses  
for populations in  
LMICs by mid 2021



**Diagnostics**  
500 million  
tests to LMICs  
by mid-2021

Act Now. Act Together. Act to end COVID-19.

BILL & MELINDA  
GATES foundation

dcvmn  
Developing Countries Vaccine  
Manufacturers Network

TheGlobalFund

IGBA  
INTERNATIONAL GENETIC AND  
BIOMIMETIC ASSOCIATION

W  
wellcome

CEPI

Gavi  
The Vaccine Alliance

IFPMA  
International Federation  
of Pharmaceutical  
Manufacturers & Associations

Unitaid  
Innovation in Global Health

World Health  
Organization

# Science is delivering, there is a light at the end of the tunnel


## Total number of COVID-19 vaccine candidates

347



Total number of vaccines

## Vaccines by vaccine type



## Total doses committed in deals so far


10 932 180 000



Doses committed so far


## Average number participants in phase III clinical trials

15 083



Average number of participants in phase III COVID-19 vaccine trials

# Challenges remain in scaling up manufacturing capacities



Unprecedented scale-up of manufacturing up to 12-15 billion doses worldwide → altering facilities, hiring and training staff



Syringes/vials to be filled in sterile environments, packaged, and shipped at appropriate temperatures and conditions



Fill and finish - immediate need is for billions of doses which can overwhelm the machinery

- All countries will not get the same proportion of vaccines upfront.
- Initial aim will be to have enough doses to protect **healthcare workers, people with underlying health conditions and the elderly, irrespective of where they live.**

*If we are to protect healthcare workers worldwide, that would represent **1%** of the total number of new vaccines needed. If we include high risk people, then it would be **20%**.*

# Safety of vaccinated individuals is the top priority in development of COVID-19 vaccines

- We respect concerns people may have about the safety of vaccines.
- Recognizing the industry's role in building and sustaining vaccine confidence by developing high quality, safe and effective vaccines.
- We are developing vaccines as fast as possible, and as slow as needed to ensure safety and quality – vaccine speed must not trump safety.
- No short cuts have been taken by IFPMA members in developing COVID-19 vaccines despite the urgency.

## FINANCIAL TIMES

Opinion **Coronavirus treatment**

### Vaccine speed must not trump safety

Manufacturers know Covid-19 jabs are the wrong arena for currying political favour

THOMAS CUENI

[+ Add to myFT](#)



A centre in Manama, Bahrain, where a large-scale trial of a Chinese-sponsored vaccine for Covid-19 is being carried out © Mazen Mahdi/AFP/Getty

# Historic unparalleled immunization has started

- Country readiness and delivery is now crucial.
- It will be imperative to work in concerted efforts and collaboration **to build trust** in COVID-19 vaccines.
- IFPMA and its members work with key global organizations to inform the public on the development and introduction of COVID-19 vaccines, including through COVID-19 vaccines confidence digital communication campaign



Source: BBC News (<https://www.bbc.com/news/uk-england-coventry-warwickshire-55243602>)



# Thank you

**Thomas B. Cueni**

Director General

International Federation of Pharmaceutical Manufacturers & Associations

